Recent Updates
Recently added Catalysts

Ocular Therapeutix, Inc.

OCULFDA catalysts, PDUFA dates & pipeline intelligence
$6.02
▲ +0.01 · +0.17%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full OCUL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $5.8052W HIGH $16.44
Volume
6.30 M
Value Traded
37.95 M
Short % Float
14.42%
Days to Cover
10.1
-9.61%Week
-4.29%1 Month
-48.68%3 Month
-25.03%6 Month
-42.57%5 Year
-36.69%All Time

Cash Data

Unlock OCUL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.32 B
EPS (TTM)
-1.49
P/E Ratio
-
Ent. Value
793.93 M
Total Shares
220.02 M
Float Shares
201.14 M
Insiders
8.58%
Institutions
91.44%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 interim results
AXPAXLI (OTX-TKI)
wet age-related macular degeneration (wet AMD)
Phase 3Small MoleculesOphthalmology
Unlock every OCUL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

OCUL Catalyst Timeline

Dated clinical, regulatory and corporate events for Ocular Therapeutix, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ocular Therapeutix, Inc.

560Total events
8Upcoming
98Tier-1 (high impact)
2015 to 2028Coverage

Upcoming catalysts 2

T1NDA Submission
Subscribe to view catalyst details
AXPAXLI
T1NDA Submission
Subscribe to view catalyst details
AXPAXLI

Event history 50

●Quarterly UpdateCorporate
Third Quarter 2026 financial results reported
●Equity OfferingCorporate
Inducement equity awards granted to eight newly hired non-executive employees
●Equity OfferingCorporate
Inducement equity awards granted to 15 newly hired non-executive employees
▲Pre NDA MeetingAXPAXLIFDA Meeting
Positive Pre-NDA Meeting with FDA completed for AXPAXLI wet AMD NDA
wet age-related macular degeneration (wet AMD)source ↗
●Protocol AmendmentAXPAXLITrial
HELIOS-3 trial design amended
diabetic retinopathysource ↗
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
◆Pre NDA MeetingAXPAXLIFDA Meeting
Pre-NDA meeting scheduled with FDA
wet AMDsource ↗
◆R&D DayPresentation
Investor Day in New York City
●Oral PresentationPresentation
Investor Day presentation
◆Oral PresentationAXPAXLIPresentation
HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy
nonproliferative diabetic retinopathysource ↗
Unlock the full OCUL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How OCUL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-12OTX-TKI (intravitreal axitinib hydrogel / Axpaxli) Phase 3 data presentation Phase 3
Unlock 14 more OCUL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 15%
Micro Cap
(rank 110 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
DEXTENZA
Showing 8 of 15 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
OTX-TKI Small MoleculesNCT06495918Neovascular Age-related Macular DegenerationPhase 3 ACTIVE NOT_RECRUITING 2,069Jan 8, 2027
OTX-TKI Small MoleculesNCT07235085Non-Proliferative Diabetic RetinopathyPhase 3 RECRUITING 930Mar 1, 2027
OTX-TIC low dose Travoprost Intracameral Small MoleculesCompletedNCT05335122Open Angle GlaucomaPhase 2 COMPLETED 83Jan 24, 2025
OTX-TIC Medical DevicesCompletedNCT04360174Ocular HypertensionPhase 1 COMPLETED 19May 24, 2021
OTX-DED Small MoleculesCompletedNCT05814757Dry Eye SyndromesPhase 2 COMPLETED 100May 22, 2024
OTX-DED Small MoleculesCompletedNCT04747977Dry EyePhase 2 COMPLETED 172Sep 22, 2021
OTX-CSI Small MoleculesCompletedNCT04362670Dry Eye DiseasePhase 1/2 COMPLETED 153Aug 11, 2021
Dextenza Insert Small MoleculesNot countedNCT04539548CataractPhase 3 COMPLETED 65Dec 21, 2023
Unlock the OCUL pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every OCUL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
AXPAXLI wet AMDPhase 32026-04-13median time of 39 weeks and 46 weeks to≥30 and≥75 uM increases from Week 8; median time to ≥30 uM Central Subfield Thickness (CSFT) increase from Week 8 was 39 weeks in the AXPAXLI group and 16 weeks in the aflibercept (2 mg) group, a 23-week difference; estimated hazard ratio of 0.7Read MoreOcular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMDRead More
Scroll for more · summaries link to the source press release
Unlock every OCUL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock OCUL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Saroj NamrataOfficer (Chief Business Officer)Sell -35,370 220,522 held$6.55 11/05/2026
Unlock the full OCUL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 2.7 % (-3.6 %) 168.28 M 21.94 M 11.45% ( 2.25 M)
Unlock every fund holding OCUL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in OCUL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see OCUL ownership
Insider and institutional ownership, quarter by quarter.

OCUL Short Interest

Shares sold short, counted twice a month.

14.42%
Short % of Float
of tradable shares sold short
29.0M
Shares Sold Short
+0.8% vs prior count
10.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Unlock OCUL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock OCUL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live OCUL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock OCUL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How OCUL ranks across every disease it competes in

Competitive Position is a premium feature
See how OCUL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

OCUL News

OCUL
Nov 9, 2026
OCULFDA Updates

Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix reported its Q3 2026 financial results, highlighting the NDA submission for AXPAXLI for wet AMD, expected in 4Q 2026. The company noted positive outcomes from the SOL-1 trial, with 70% of subjects remaining dry at Week 36. However, it also reported a net loss of $(94.8) million and a decrease in revenue compared to the previous year.

Read more →
OCUL
Nov 6, 2026
OCULGeneral

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix announced the grant of inducement equity awards to eight new non-executive employees. The awards include stock options for 35,775 shares and restricted stock units for 11,725 shares, effective November 2, 2026. These grants are part of the company's strategy to attract talent under its 2019 Inducement Stock Incentive Plan.

Read more →
OCUL
Nov 2, 2026
OCULConferences/Events

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

Ocular Therapeutix will host a conference call on November 9, 2026, to discuss its third quarter financial results. The company is advancing its investigational product AXPAXLI in Phase 3 trials for wet AMD and diabetic retinal disease. Additionally, it has a pipeline that includes the FDA-approved DEXTENZA and the OTX-TIC candidate.

Read more →
OCUL
Oct 29, 2026
OCULConferences/Events

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

Ocular Therapeutix announced its participation in several investor and scientific conferences in November 2026. Key events include a fireside chat at the UBS Global Biopharma Conference and presentations at The Empire Forum and OSN New York. The discussions will focus on advancements in retinal disease treatments.

Read more →
OCUL
Oct 1, 2026
OCULConferences/Events

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in October 2026. Highlights include presentations on their investigational product AXPAXLI for retinal diseases at major events like the Chardan Healthcare Conference and the American Academy of Ophthalmology. The company aims to redefine the retina experience through innovative therapies.

Read more →
OCUL
Sep 15, 2026
OCULFDA Updates

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Ocular Therapeutix announced a successful Pre-NDA Meeting with the FDA for AXPAXLI, an investigational treatment for wet AMD. The company is on track to submit the NDA in Q4 2026, based on robust efficacy and safety data from clinical trials. AXPAXLI could become the first TKI approved for wet AMD, with commercial preparations underway for a potential 2027 launch.

Read more →
OCUL
Sep 1, 2026
OCULConferences/Events

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

Ocular Therapeutix, Inc. will participate in several investor and scientific conferences in September and October 2026. Key events include the Wells Fargo Healthcare Conference and the Retina Society Annual Meeting, where they will present findings on their investigational product AXPAXLI for retinal diseases. The company aims to highlight advancements in treatment options for conditions like wet AMD.

Read more →
OCUL
Aug 3, 2026
OCULFDA Updates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix reported its Q2 2026 financial results, highlighting progress on the NDA submission for AXPAXLI for wet AMD, expected in Q4 2026. The company confirmed FDA alignment and presented data suggesting a significant reduction in treatment burden with AXPAXLI. Despite a net loss of $(78.8) million, Ocular maintains a strong cash position to support its operations into 2028.

Read more →
OCUL
Jul 1, 2026
OCULConferences/Events

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences in July 2026. Key presentations will focus on advancements in retinal therapies, including results from the Phase 3 SOL-1 trial for AXPAXLI. The company aims to redefine the retina experience through innovative treatments and ongoing clinical trials.

Read more →
OCUL
Jun 17, 2026
OCULFDA Updates
▲ +7.8%on this news

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Ocular Therapeutix announced its plans to submit a New Drug Application (NDA) for AXPAXLI in wet AMD by Q4 2026, based on positive SOL-1 trial data. The company will conduct an interim safety analysis for the SOL-R trial to meet FDA requirements. AXPAXLI aims to differentiate itself from existing treatments like aflibercept, with a new secondary endpoint added to the SOL-R trial. The company is also streamlining its diabetic retinopathy program to focus on the HELIOS-3 trial.

Read more →
OCUL
Jun 4, 2026
OCULConferences/Events
▲ +5.4%on this newsshared move

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix, Inc. announced its participation in the Clinical Trials at the Summit 2026, held on June 12-13 in Las Vegas, Nevada. The event includes presentations on the company's investigational product AXPAXLI, aimed at treating neovascular AMD and diabetic retinal diseases. Significant discussions will focus on the safety and efficacy outcomes of OTX-TKI. This participation emphasizes Ocular's dedication to innovation and leadership in retinal disease therapies.

Read more →
OCUL
Jun 2, 2026
OCULConferences/Events
▼ -6.9%on this newsshared move

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from company leadership and retinal disease experts. The event will cover the NDA submission plan for AXPAXLI in wet AMD, updates on ongoing trials, and commercialization strategies. A live Q&A session and networking reception will conclude the event.

Read more →

About Ocular Therapeutix, Inc.

Bedford, MA 325 employees ocutx.com
Headquarters14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
BIOPHARMAWATCH ELITE
Trade the next OCUL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime